Protective Effect of Delayed Treatment With Low-Dose Glibenclamide in Three Models of Ischemic Stroke

J. Marc Simard, MD, PhD; Vladimir Yurovsky, PhD; Natalia Tsymbalyuk, MS; Ludmila Melnichenko, MS; Svetlana Ivanova, PhD; Volodymyr Gerzanich, MD, PhD

Background and Purpose—Ischemia/hypoxia induces de novo expression of the sulfonylurea receptor 1-regulated NC(Ca-ATP) channel. In rodent models of ischemic stroke, early postevent administration of the sulfonylurea, glibenclamide, is highly effective in reducing edema, mortality, and lesion volume, and in patients with diabetes presenting with ischemic stroke, pre-event plus postevent use of sulfonylureas is associated with better neurological outcome. However, the therapeutic window for treatment with glibenclamide has not been studied.

Methods—We examined the effect of low-dose (nonhypoglycemic) glibenclamide in 3 rat models of ischemic stroke, all involving proximal middle cerebral artery occlusion (MCAo): a thromboembolic model, a permanent suture occlusion model, and a temporary suture occlusion model with reperfusion (105 minutes occlusion, 2-day reperfusion). Treatment was started at various times up to 6 hours post-MCAo. Lesion volumes were measured 48 hours post-MCAo using 2,3,5-triphenyltetrazolium chloride.

Results—Glibenclamide reduced total lesion volume by 53% in the thromboembolic MCAo model at 6 hours, reduced corrected cortical lesion volume by 51% in the permanent MCAo model at 4 hours, and reduced corrected cortical lesion volume by 41% in the temporary MCAo model at 5.75 hours (P<0.05 for all 3). Analysis of pooled data from the permanent MCAo and temporary MCAo series indicated a sigmoidal relationship between hemispheric swelling and corrected cortical lesion volume with the half-maximum cortical lesion volume being observed with 10% hemispheric swelling.

Conclusions—Low-dose glibenclamide has a strong beneficial effect on lesion volume and has a highly favorable therapeutic window in several models of ischemic stroke. (Stroke. 2009;40:604-609.)

Key Words: cerebral ischemia \(\text{SUR1}\) glibenclamide stroke \(\text{SUR1}\)-regulated NC\(\text{Ca-ATP}\) channel

The sulfonylurea receptor 1 (SUR1)-regulated NC\(\text{Ca-ATP}\) channel is a 30 pS channel that conducts monovalent but not divalent cations.\(^1\) This channel is not constitutively expressed but is newly upregulated in neurons, astrocytes, and capillary endothelial cells after central nervous system ischemia or injury. Channel opening, which is triggered by ATP depletion, has been implicated in oncotic cell swelling and oncotic cell death.\(^2-4\) Block of the channel by glibenclamide and other SUR1 inhibitors soon after an insult results in significant improvements in rodent models of ischemic stroke and spinal cord injury.\(^5,5\)

Unlike most putative neuroprotective drugs, available evidence suggests that glibenclamide may benefit humans with ischemic stroke. A retrospective study has shown that, in patients with diabetes mellitus who present with an ischemic stroke, those already taking glibenclamide or another sulfonylurea drug and who continue on it fare significantly better than matched patients with diabetes not on a sulfonylurea drug.\(^6\)

To date, no study has examined the therapeutic window for glibenclamide. We examined the effect of glibenclamide administered with a delay of 2 to 6 hours after onset of focal cerebral ischemia. Because humans with ischemic stroke have various sorts of insults, including thromboembolic strokes, permanent occlusions as well as transient occlusions, we sought to evaluate the effect of glibenclamide in models relevant to each of these conditions. We examined the efficacy of delayed administration of low-dose glibenclamide in 3 models of stroke with assessment of infarct volumes 48 hours after onset of ischemia. Our data indicate that treatment with nonhypoglycemic doses of glibenclamide is beneficial in a variety of models of ischemic stroke and with a very favorable therapeutic window.

Methods

Rat Models of Ischemic Stroke

All surgical procedures were approved by the Institutional Animal Care and Use Committee of the University of Maryland. Two...
investigators who were blinded to the treatment and who did not evaluate outcome performed all of the surgical procedures. Fasted male Wistar rats (250 to 300 g; Harlan, Indianapolis, Ind) were anesthetized (60 mg/kg ketamine and 7.5 mg/kg xylazine intraperitoneally) and allowed to ventilate air spontaneously. Temperature was maintained at 37°C using a heating pad regulated by rectal temperature (Harvard Apparatus, Holliston, Mass). For all 3 models, the right carotid sheath was exposed through a ventral midline incision, the common, external, and internal carotid arteries (CCA, ECA, ICA) were dissected and the pterygopalatine artery was ligated. Blood gases (i-STAT; Heska Corp, Ft Collins, Col), generally sampled from either the ECA or CCA shortly before middle cerebral artery occlusion (MCAo), were (mean±SD): pO₂, 90±14 mm Hg; pH, 7.38±0.04; glucose, 195±43 (n=61). Additional measurements of serum glucose were obtained at later times by bleeding the tip of the tail.

Thrombembolic Middle Cerebral Artery Occlusion Model
Thrombi used for embolization were prepared as described.7 PE50 tubing loaded with 6 thrombi approximately 1.0 mm in length that appeared white and that did not easily fragment was used to catheterize the ECA. Thrombi were flushed into the ICA using approximately 200 μL of normal saline (NS). The stump of the ECA was ligated and flow was restored in the CCA/ICA.

Permanent Middle Cerebral Artery Occlusion Model
Thread occluders were manufactured using 4–0 monofilament nylon with occluder tips of 0.35×5 mm molded from silicone polymer (Sylgard 184; Dow Corning Corp, Midland, Mich) using PE20 tubing.8 The CCA was catheterized and flushed with 200 μL of warm NS. The occluder was introduced into the CCA, was advanced into the ICA approximately 18 mm from the CCA bifurcation until resistance was felt, and was secured in place.

Temporary Middle Cerebral Artery Occlusion Model
Relative cerebral blood flow (rCBF) was measured using a laser Doppler flowmeter (Moore Instruments, Axminster, UK). After thinning the skull 2 mm caudal and 4 mm lateral to bregma, the laser Doppler probe was affixed to the skull using a-cyanoacrylate adhesive. The ICA was flushed with 200 μL of warm NS and MCAo was performed by inserting the occluder, manufactured as previously, retrograde into the ICA stump, and advancing it under guidance of the flowmeter. Animals with a drop in rCBF <75% were not further studied. After 105 minutes, the occluder was removed, the ECA stump was ligated, and flow was restored in the CCA/ICA. The rat was maintained under anesthesia throughout the period of occlusion, and rCBF was monitored continuously, including for 10 minutes after reperfusion. rCBF values were calculated as a percentage of the immediate preocclusion baseline.

Treatment
Stock solutions of glibenclamide (Sigma, St Louis, Mo) were prepared in dimethylsulfoxide (5 mg/mL). Solutions for delivery were prepared by adding stock solution to NS and clarifying the solution as needed using a minimum amount of NaOH to a pH approximately 8 to 8.5. Solutions prepared in this way and stored at 37°C for 48 hours retained >80% efficacy as measured in patch clamp experiments on K₁₉₅₉ channels in insulinoma cells. Infusion doses were delivered using a subcutaneously implanted miniosmotic pump (Model 2001; 1.0 μL/h; Durect Corp, Cupertino, Calif), which was always implanted immediately after MCAo. For delayed treatment, pumps were fitted with a catheter containing air (“spacer substance”) to produce the desired delay (see Supplemental Material, available online at http://stroke.ahajournals.org). Loading doses, which were used only with delayed treatment, were delivered intraperitoneally at the designated time. For the thromboembolic MCAo series, we used an infusion dose of 75 ng/h and, for delayed treatments, a loading dose of either 3.3 μg/kg or 33 μg/kg. For the permanent MCAo series, we used an infusion dose of 200 ng/h and a loading dose of 33 μg/kg. For the temporary MCAo series, we used an infusion dose of 200 ng/h and a loading dose of 10 μg/kg. Controls were administered vehicle (NS plus dimethylsulfoxide) in the same way.

Exclusion Criteria
Animals were excluded for: subarachnoid hemorrhage (9% to 10%/treatment group); total lesion volume <10% before correction; malpositioned occluder (permanent MCAo model); rCBF reduction <75% or inadequate reperfusion (temporary MCAo model). Deaths (<5%/group), typically occurring within 4 hours of MCAo, were attributable to anesthesia or surgery with no stroke-related deaths encountered.

Immunohistochemistry
Some rats from the temporary MCAo series were used for immunohistochemistry. After transcardiac perfusion/fixation with paraformaldehyde and cryoprotection with 30% sucrose, cryosections were immunolabeled using primary antibodies directed against SUR1 (C-16; Santa Cruz Biotechnology, Santa Cruz, Calif; diluted 1:200; 1 hour at room temperature, 48 hours at 4°C) or IgG (Santa Cruz). Alexa Fluor 550- or fluorescein isothiocyanate-conjugated secondary antibodies (Jackson Immunoresearch, West Grove, Pa) were used. Slides were coverslipped with ProLong Gold antifade reagent containing 4′,6-diamino-2-phenylindole for nuclear staining (P36935; Invitrogen, Carlsbad, Calif).

Stroke Outcome Measures and Data Analysis
All rats used for assessment of lesion size were euthanized 48 hours post-MCAo; 2-mm coronal sections were immersed in 2% 3,3,5-triphenyltetrazolium chloride (Sigma-Aldrich) in NS for 20 minutes at 37°C. Images of 2,3,5-triphenyltetrazolium chloride-stained sections, obtained using a flatbed scanner, were analyzed using Photoshop (Adobe), which allowed tracings to be stored for later review by a different investigator. Area measurements made in pixels on 5 consecutive slices were converted to mm³ or percent hemisphere. For the temporary MCAo series, the measurements collected consisted only of the size of the 2,3,5-triphenyltetrazolium chloride(-) lesion and of the ipsilateral hemisphere, which allowed calculation of the total uncorrected lesion volume. For the permanent MCAo and the temporary MCAo series, the data collected included the size of the cortical 2,3,5-triphenyltetrazolium chloride(-) lesion of the ipsilateral and contralateral cortex and of the ipsilateral and contralateral hemisphere, which allowed calculation of the cortical lesion volume corrected for swelling and of hemispheric swelling.

Statistical significance was assessed using either Student t test (permanent MCAo series) or one-way analysis of variance (thromboembolic MCAo and temporary MCAo series) with Bonferroni group comparisons. To analyze the relationship between hemispheric swelling and cortical lesion volume, data from the permanent MCAo and temporary MCAo series were pooled and were fit to a sigmoid function, LV=LVmax/(1+e⁻β), where LV=lesion volume, LVmax=maximum lesion volume, and B=(HS-HSbaseline)/HS=hemisphere swelling, HSbaseline=value of HS at which LV is half maximum, and s is a measure of the steepness of the curve.

Maps of the spatial density of the probability of infarction (POI) were prepared using sections from each of the 5 groups of rats in the temporary MCAo series (CTR and 2 treatment groups). The 2,3,5-triphenyltetrazolium chloride image from each rat at −2 mm from bregma was processed (Abode Photoshop). The “green channel” of each RGB image had its “opacity” set by an amount equal to the reciprocal of the number of sections in the group. Processed sections for each group were overlaid to generate a “pseudoaverage” image. The resulting 3 images, one for each group, were then processed identically to display the spatial density of POI with white pseudocolor denoting a probability of 1 and black pseudocolor denoting a probability of 0.

Results

Lesion Volume
For the thromboembolic MCAo series, total lesion volumes with no delay in glibenclamide treatment (no loading dose)
and with 2-hour delay (loading dose, 3.3 μg/kg) were significantly smaller than in controls (Figure 1A). The benefit of glibenclamide was lost when treatment was started at 4 or 6 hours post-MCAo with a low loading dose (3.3 μg/kg) but was regained with a higher loading dose (33 μg/kg). The data with 4-hour delay showed a trend that was not statistically significant (P=0.07), whereas the data with 6-hour delay were statistically different from controls.

For the permanent MCAo series, corrected cortical lesion volumes with 4-hour delay were significantly smaller than in controls (Figure 1B). For the temporary MCAo series, values for the reduction in rCBF were not different between groups (82±2, 81±2, and 84±2 for controls and the groups with 1¾-hour and 5¾-hour delays, respectively). Corrected cortical lesion volumes with 1¾-hour and 5¾-hour delays were both significantly smaller than in controls (Figure 1C).

Swelling
A scatterplot of the pooled data from both the permanent MCAo and temporary MCAo series, both with and without treatment, demonstrated a homogeneous sigmoidal relationship between hemispheric swelling and corrected cortical infarct volume (Figure 2). Fit of the data with a sigmoid function indicated half-maximum cortical lesion volume (35%) occurring with 9.8% hemispheric swelling (maximum cortical lesion volume, 70%).

Glucose
The glycemic response to anesthesia plus surgery was similar in vehicle-treated controls and in rats treated with glibenclamide (Figure 3A). Higher doses of glibenclamide than those used for treatment did not reduce serum glucose below 100 mg/dL (Figure 3B).

Probability of Infarction
Maps of the spatial density of POI, constructed using data from the temporary MCAo series, showed that the cortex could be divided into 4 relatively distinct regions where POI correlated with proximity to the middle cerebral artery origin (Figure 4): Region 1, dorsal/medial cortex, supplied by the
anterior cerebral artery with POI approximately 0; Region 2, dorsal/lateral cortex, the most-distal middle cerebral artery territory with POI approximately 1; Region 3, lateral cortex, the intermediate middle cerebral artery territory with POI intermediate; and Region 4, inferior/lateral cortex, the most-proximal portion of the middle cerebral artery territory with POI lowest. Glibenclamide had no effect on Regions 1 or 2, whereas it reduced the POI by approximately half in Regions 3 and 4 (Figure 4D).

Delayed Sulfonylurea Receptor 1 Expression Post–Middle Cerebral Artery Occlusion

We hypothesized that the beneficial effect of glibenclamide observed in Regions 3 and 4, despite a delay in treatment, might be related to delayed upregulation of its target, SUR1, because in a model of malignant cerebral edema, maximal expression of SUR1 occurs only at 8 hours.4 We assessed SUR1 expression and IgG labeling, with the latter serving as a marker of vasogenic edema and cellular demise.9 In Regions 3 and 4 at 5 3⁄4 hours, relatively little SUR1 expression was evident and IgG labeling was largely absent (Figure 5). In the same regions at 24 hours, however, both SUR1 expression and IgG labeling were prominent throughout the cortex, including in neurons and microvessels, consistent with delayed SUR1 expression and worsening tissue demise after 5 3⁄4 hours (Figure 5).

Discussion

The assessment of purported neuroprotective agents should include studies with comorbidities and testing in a wide scope of models including in vitro and in vivo models, with the latter including transient and permanent occlusion and testing of efficacy with delayed treatment.10–12 The studies presented here and previously have begun to address these objectives for glibenclamide.

Comorbidity: Hyperglycemia

Admission hyperglycemia complicates approximately one third of acute ischemic strokes and is associated with a worse clinical outcome.13 Our use of ketamine/xylazine anesthesia produced hyperglycemia with mean serum glucose levels approximately 200 mg/dL at the time of MCAO,14 which could adversely affect outcome.15 Our data indicated that glibenclamide was effective in reducing mortality4 as well as lesion volume (this study) despite the presence of hyperglycemia at the time of onset of ischemia. Notably, the loading doses of glibenclamide used in both of our studies were 40 to 400 times less than typically used to induce hypoglycemia in rats.16 However, the data of Figure 3 suggest that glucose levels fell somewhat more rapidly in rats treated with glibenclamide compared with controls. Although no literature suggests that such small differences would account for the magnitude of protection observed, nevertheless, additional study of this question may be warranted.

Scope of Testing: Cell Systems, Animal Models, and Humans

Glibenclamide reduces depolarization, oncotic cell swelling, and oncotic cell death induced by ATP depletion in isolated neurons, astrocytes, and central nervous system endothelial cells that express the SUR1-regulated NCx,ATP channel,3–5 providing important information about cellular and molecular mechanisms of drug action.
We recently reported that contemporaneous use of sulfonylureas in human diabetics presenting with ischemic stroke is associated with significantly better outcomes measured as an improvement in National Institutes of Health Stroke Scale and in modified Rankin scale at approximately 2 weeks.6 We have now studied the effect of the sulfonylurea, glibenclamide, in 4 different models of ischemic stroke: a model of malignant cerebral edema,4 a thromboembolic model, a permanent occlusion model, and a temporary occlusion model with reperfusion. The study in humans suggested that sulfonylureas are beneficial mainly in the context of large vessel disease. Our work with animal models, all of which have involved proximal large vessel occlusions, reaffirms this. Another important variable that affects stroke outcome is the presence or absence of reperfusion after an ischemic event.17 Two of our 4 models involved permanent MCAo without reperfusion, and 2 involved temporary MCAo with reperfusion. The 2 reperfusion models included a thromboembolic model associated with spontaneous reperfusion occurring at undetermined times18,19 and a standard temporary suture occlusion model with predetermined 105-minute occlusion and reperfusion that were strictly documented with LDF. Glibenclamide showed a strong beneficial effect in all 4 models; it reduces edema and mortality in the malignant cerebral edema model,4 it improves rCBF in the thromboembolic MCAo model,4 and we show that it significantly reduced lesion volume in the 3 nonlethal models. Overall, our data indicate that glibenclamide confers significant protection from ischemic injury in a variety of models relevant to the human condition.

One limitation of the present study is that end points were measured 48 hours after onset of ischemia with treatment continued throughout. Additional studies will be required to determine the optimal duration of treatment required and the durability of treatment.

**Treatment Window**

Our data suggest that glibenclamide has a favorable window of treatment. A significant beneficial effect on stroke outcome was observed in humans already on (“pretreated with”) sulfonylureas at the time of their ischemic event.6 In our previous report on the malignant cerebral edema model,4 as well as here with the thromboembolic MCAo model, we studied the effect of glibenclamide when drug was administered with nominally no delay in treatment. In these cases, treatment was effected by implanting a miniosmotic pump shortly after MCAo with no loading dose administered. Pharmacokinetic analysis (clearance, 5.8 mL/min/kg)16 indicated that the infusion rates used (75 or 200 ng/h) would require approximately 3 hours to reach 90% of steady-state levels, rendering these experiments, in actuality, studies of delayed treatment. We also examined the effect of a deliberate delay in treatment out to 6 hours after onset of ischemia. Strong protection was found when delayed treatment included use of a sufficient loading dose. Because of uncertainties with thromboembolic models, specifically with delayed reperfusion at unpredictable times,18,19 we place less emphasis on our data with the thromboembolic MCAo model. However, our data with the temporary MCAo model are robust with clear documentation of the degree (>75% reduction in CBF) and duration (105 minutes) of ischemia. With the temporary MCAo model, treatment beginning 5¼ hours after onset of ischemia showed a strong protective effect. The therapeutic window for glibenclamide compares favorably with other treatments; human albumin is beneficial when administered out to 4 hours, but not 5 hours after onset of ischemia (120-minute temporary MCAo/3-day reperfusion)20; minocycline is beneficial at 4 hours (90-minute temporary MCAo/3-day reperfusion)21 and at 5 hours but not at 6 hours (90-minute temporary MCAo/1-day reperfusion).22

The favorable treatment window observed with glibenclamide probably relates to the fact that SUR1-regulated NC3aATP channels are not constitutively expressed, but are expressed de novo over the course of several hours postinsult. In the malignant cerebral edema model, SUR1 is upregulated early (<3 hours) in the core and then disappears as necrosis sets in, whereas in penumbra, SUR1 is upregulated later with maximum expression at 8 hours.4 In the temporary MCAo model, an important part of the salvageable penumbra was the inferior/lateral cortex (Regions 3 and 4), where at 5¼ hours, IgG labeling for leakage and cellular damage was largely absent and SUR1 upregulation was relatively modest compared with sharp increases in both at 24 hours. SUR1 expression, vascular leakage, and cellular uptake of IgG were dynamic processes that progressed gradually over many hours postevent, consistent with the observation of a prolonged window of time during which a beneficial effect of glibenclamide could be observed.

**Pathophysiology**

Several mechanisms by which glibenclamide could potentially act to effect protection can be excluded. Ischemic tolerance is unlikely to have been important, because ischemic tolerance induced by various treatments including adenosine23 and hypothermia24 is abolished by glibenclamide. Induction of hypoglycemia is unlikely to have been important, because the doses of glibenclamide used were not hypoglycemicogenic (Figure 3), suggesting minimal action on either pancreatic β cells or hypothalamic KATP channels that are important for glycemic control. An effect on temperature is unlikely, because glibenclamide does not affect hypothalamic temperature regulation and does not protect neuronal activity from the effects of an increase in temperature.25 Finally, augmentation of rCBF is unlikely, because glibenclamide does not affect CBF normally,26 and it attenuates compensatory increases in CBF associated with hypoxia27 and hypercapnia.28

Our analysis indicated that cortical lesion size was closely related to hemispheric swelling (Figure 2).29 Hemispheric swelling of 10% yielded half-maximum cortical infarction, and hemispheric swelling of 20% or more yielded maximum cortical infarction. For a rat hemisphere with a volume of 600 μL, 10% to 20% swelling would add 60 to 120 μL, which, if abruptly infused, would be enough to increase intracranial pressure above mean venous pressure or even above mean arterial pressure30 and thereby impair tissue perfusion. Our analysis also indicated that the apparent probability of infarcting a given region of cortex correlated with how distal that
territory was from the middle cerebral artery origin (Figure 4). Overall, these findings are not unexpected; relative flow in vessels decreases as they branch ever more distantly from their source, and flow decreases with both increasing tissue pressure and with increasing vascular resistance (Darcy’s law,\textsuperscript{31} F = ΔP/R, where F is blood flow, ΔP is mean arterial pressure minus venous pressure, with venous pressure determined by tissue pressure, and R is vascular resistance). Swelling thus preferentially affects more distal middle cerebral artery territories as tissue pressure from edema increases and as resistance of pial vessels increases due to their being forced against the inner table of the skull.

The data presented in Figure 2 demonstrate that glibenclamide treatment was associated with a reduction in hemispheric swelling, reaffirming previous findings that glibenclamide is highly effective at blocking cellular edema and ionic edema,\textsuperscript{2–4} which together are the main determinants of spheric swelling, reaffirming previous findings that glibenclamide is protective in a rat model of thromboembolic stroke.\textsuperscript{19}

Simard et al Glibenclamide and Stroke 609

Sources of Funding

This work was supported by grants (to J.M.S.) from the National Institute of Neurological Disorders, and Stroke (NS048260).

Disclosures


References

4. Simard JM, Chen M, Tarasov KV, Bhatta S, Ivanova S, Melnitchenko L, Tsymbalyuk N, West GA, Gerzanich V. Newly expressed SUR1-regulated NC\textsubscript{Ca-ATP} channel.\textsuperscript{4} Effective prevention of swelling, coupled with direct prevention of cell death, may account for the strong protective effect of glibenclamide.

Protective Effect of Delayed Treatment With Low-Dose Glibenclamide in Three Models of Ischemic Stroke

J. Marc Simard, Vladimir Yurovsky, Natalia Tsymbalyuk, Ludmila Melnichenko, Svetlana Ivanova and Volodymyr Gerzanich

Stroke. 2009;40:604-609; originally published online November 20, 2008; doi: 10.1161/STROKEAHA.108.522409

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://stroke.ahajournals.org/content/40/2/604

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Stroke can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Stroke is online at:
http://stroke.ahajournals.org//subscriptions/